rFVIIa in ICH in Patients Treated With Anticoagulants or Anti-Platelets

Status Recruiting

Clinical Trial Summary

Evaluation of efficacy and safety of recombinant factor VIIa versus standard therapy in preventing early haematoma growth in spontaneous acute intracerebral haemorrhage in patients treated with oral anticoagulants or antiplatelets agents

Clinical Trial Description

Intracerebral hemorrhage (ICH) is the deadliest, most disabling, and least treatable form of stroke. Approximately 40% of patients die within 1 month of ICH onset, and two-thirds of survivors never regain functional independence. Though guidelines for supportive care exist, there is currently no treatment that has been shown in a randomized-controlled trial to definitely improve outcome after ICH. Hematoma volume is a critical determinant of mortality and functional outcome after ICH, and early hematoma growth may be an important cause of early neurological deterioration.

Considerable clinical interest has been given to the relationship between antiplatelet and antithrombotic treatment and ICH.

The reported incidence of major bleeding events in patients undergoing antithrombotic treatment is 5-11/1,000 patients/year, while the overall range of hemorrhages is about 62/1,000 patients/year.In the patients treated with antithrombotic drugs (oral anticoagulants or antiplatelets agent) the incidence rate of ICH has been shown higher than in the general population. Moreover, the mortality rate for both spontaneous and post-traumatic events is higher in antithrombotic treated patients than in controls. [14,15] rFVIIa has been successfully used to control ICH in patients with hemophilia or other coagulation disorders, and can arrest intraoperative bleeding and reverse coagulopathies in patients undergoing neurosurgical procedures.[19] rFVIIa has also been reported to prevent or minimize refractory bleeding in non-coagulopathic patients. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00222625
Study type	Interventional
Source	University Of Perugia
Contact	Alfonso Iorio, MD
Phone	075 578 4306
Email	iorioa@unipg.it
Status	Recruiting
Phase	Phase 2
Start date	September 2005
Completion date	September 2006

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05089331` - ROSE-Longitudinal Assessment With Neuroimaging
Recruiting	`NCT03605381` - MORbidity PRevalence Estimate In StrokE
Active, not recruiting	`NCT04522102` - Antiplatelet Secondary Prevention International Randomised Trial After INtracerebral haemorrhaGe (ASPIRING)-Pilot Phase	Phase 3
Terminated	`NCT04178746` - PRONTO: Artemis in the Removal of Intraventricular Hemorrhage in the Hyper-Acute Phase
Not yet recruiting	`NCT03956485` - Multicentre Registry of Patients With Spontaneous Acute Intracerebral Hemorrhage in Catalonia (HIC-CAT).
Enrolling by invitation	`NCT02920645` - Multicenter Validation of the AVICH Score	N/A
Recruiting	`NCT02625948` - Tranexamic Acid for Acute ICH Growth prEdicted by Spot Sign	Phase 2
Completed	`NCT02478177` - Addressing Real-world Anticoagulant Management Issues in Stroke
Completed	`NCT01971359` - Clinical Outcomes Following Parafascicular Surgical Evacuation of Intracerebral Hemorrhage: A Pilot Study	N/A
Terminated	`NCT00990509` - Albumin for Intracerebral Hemorrhage Intervention	Phase 2
Completed	`NCT01261091` - Early Tracheostomy in Ventilated Stroke Patients	N/A
Completed	`NCT00716079` - The Second Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial	N/A
Recruiting	`NCT05095857` - The Anesthetic Ketamine as Treatment for Patients With Severe Acute Brain Injury	Phase 4
Recruiting	`NCT04548596` - NOninVasive Intracranial prEssure From Transcranial doppLer Ultrasound Development of a Comprehensive Database of Multimodality Monitoring Signals for Brain-Injured Patients
Not yet recruiting	`NCT06429332` - International Care Bundle Evaluation in Cerebral Hemorrhage Research	Phase 4
Recruiting	`NCT05492474` - Cranial Ultrasound for Prehospital ICH Diagnosis	N/A
Not yet recruiting	`NCT05502874` - Multicenter Registry for Assessment of Markers of Early Neurological Deterioration in Primary Intracerebral Hemorrhage
Recruiting	`NCT04604587` - MRI-visible Enlarged Perivascular Spaces and the Alteration of Lymphatic Drainage System in CAA	Phase 3
Recruiting	`NCT05504941` - Detection of an Endovascular Treatment Target in Patients With an Acute, Spontaneous Intracerebral Hemorrhage	N/A
Not yet recruiting	`NCT05066620` - Chinese Herbal Medicine in Acute INtracerebral Haemorrhage (CHAIN) Trial	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.